Cargando…

Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease

Parkinson’s disease (PD) is characterized by alpha-synuclein misfolding with subsequent intraneuronal amyloid formation and accumulation, low grade neuroinflammatory changes, and selective neurodegeneration. Available evidence suggests that the pathology usually begins in the gut and olfactory mucos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumitrescu, Laura, Marta, Daciana, Dănău, Adela, Lefter, Antonia, Tulbă, Delia, Cozma, Liviu, Manole, Emilia, Gherghiceanu, Mihaela, Ceafalan, Laura Cristina, Popescu, Bogdan Ovidiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249847/
https://www.ncbi.nlm.nih.gov/pubmed/34220443
http://dx.doi.org/10.3389/fnins.2021.689723
_version_ 1783716985635340288
author Dumitrescu, Laura
Marta, Daciana
Dănău, Adela
Lefter, Antonia
Tulbă, Delia
Cozma, Liviu
Manole, Emilia
Gherghiceanu, Mihaela
Ceafalan, Laura Cristina
Popescu, Bogdan Ovidiu
author_facet Dumitrescu, Laura
Marta, Daciana
Dănău, Adela
Lefter, Antonia
Tulbă, Delia
Cozma, Liviu
Manole, Emilia
Gherghiceanu, Mihaela
Ceafalan, Laura Cristina
Popescu, Bogdan Ovidiu
author_sort Dumitrescu, Laura
collection PubMed
description Parkinson’s disease (PD) is characterized by alpha-synuclein misfolding with subsequent intraneuronal amyloid formation and accumulation, low grade neuroinflammatory changes, and selective neurodegeneration. Available evidence suggests that the pathology usually begins in the gut and olfactory mucosa, spreading to the brain via the vagus and olfactory nerves, by a prion-like mechanism. A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction. Additionally, epidemiological data indicate a link between inflammatory bowel diseases and PD. Calprotectin and zonulin are markers of intestinal inflammation and barrier permeability, respectively. We evaluated their serum and fecal levels in 22 patients with sporadic PD and 16 unmatched healthy controls. Mean calprotectin was higher in PD, both in serum (14.26 mcg/ml ± 4.50 vs. 5.94 mcg/ml ± 3.80, p = 0.0125) and stool (164.54 mcg/g ± 54.19 vs. 56.19 mcg/g ± 35.88, p = 0.0048). Mean zonulin was also higher in PD serum (26.69 ng/ml ± 3.55 vs. 19.43 ng/ml ± 2.56, p = 0.0046) and stool (100.19 ng/ml ± 28.25 vs. 37.3 ng/ml ± 13.26, p = 0.0012). Calprotectin was above the upper reference limit in 19 PD serums and 6 controls (OR = 10.56, 95% CI = 2.17–51.42, p = 0.0025) and in 20 PD stool samples and 4 controls (OR = 30, 95% CI = 4.75–189.30, p = 0.000045). Increased zonulin was found only in the stool samples of 8 PD patients. Despite the small sample size, our findings are robust, complementing and supporting other recently published results. The relation between serum and fecal calprotectin and zonulin levels and sporadic PD warrants further investigation in larger cohorts.
format Online
Article
Text
id pubmed-8249847
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82498472021-07-03 Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease Dumitrescu, Laura Marta, Daciana Dănău, Adela Lefter, Antonia Tulbă, Delia Cozma, Liviu Manole, Emilia Gherghiceanu, Mihaela Ceafalan, Laura Cristina Popescu, Bogdan Ovidiu Front Neurosci Neuroscience Parkinson’s disease (PD) is characterized by alpha-synuclein misfolding with subsequent intraneuronal amyloid formation and accumulation, low grade neuroinflammatory changes, and selective neurodegeneration. Available evidence suggests that the pathology usually begins in the gut and olfactory mucosa, spreading to the brain via the vagus and olfactory nerves, by a prion-like mechanism. A causal relationship has not been established, but gut dysbiosis is prevalent in PD and may lead to intestinal inflammation and barrier dysfunction. Additionally, epidemiological data indicate a link between inflammatory bowel diseases and PD. Calprotectin and zonulin are markers of intestinal inflammation and barrier permeability, respectively. We evaluated their serum and fecal levels in 22 patients with sporadic PD and 16 unmatched healthy controls. Mean calprotectin was higher in PD, both in serum (14.26 mcg/ml ± 4.50 vs. 5.94 mcg/ml ± 3.80, p = 0.0125) and stool (164.54 mcg/g ± 54.19 vs. 56.19 mcg/g ± 35.88, p = 0.0048). Mean zonulin was also higher in PD serum (26.69 ng/ml ± 3.55 vs. 19.43 ng/ml ± 2.56, p = 0.0046) and stool (100.19 ng/ml ± 28.25 vs. 37.3 ng/ml ± 13.26, p = 0.0012). Calprotectin was above the upper reference limit in 19 PD serums and 6 controls (OR = 10.56, 95% CI = 2.17–51.42, p = 0.0025) and in 20 PD stool samples and 4 controls (OR = 30, 95% CI = 4.75–189.30, p = 0.000045). Increased zonulin was found only in the stool samples of 8 PD patients. Despite the small sample size, our findings are robust, complementing and supporting other recently published results. The relation between serum and fecal calprotectin and zonulin levels and sporadic PD warrants further investigation in larger cohorts. Frontiers Media S.A. 2021-06-18 /pmc/articles/PMC8249847/ /pubmed/34220443 http://dx.doi.org/10.3389/fnins.2021.689723 Text en Copyright © 2021 Dumitrescu, Marta, Dănău, Lefter, Tulbă, Cozma, Manole, Gherghiceanu, Ceafalan and Popescu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Dumitrescu, Laura
Marta, Daciana
Dănău, Adela
Lefter, Antonia
Tulbă, Delia
Cozma, Liviu
Manole, Emilia
Gherghiceanu, Mihaela
Ceafalan, Laura Cristina
Popescu, Bogdan Ovidiu
Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease
title Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease
title_full Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease
title_fullStr Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease
title_full_unstemmed Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease
title_short Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease
title_sort serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249847/
https://www.ncbi.nlm.nih.gov/pubmed/34220443
http://dx.doi.org/10.3389/fnins.2021.689723
work_keys_str_mv AT dumitresculaura serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT martadaciana serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT danauadela serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT lefterantonia serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT tulbadelia serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT cozmaliviu serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT manoleemilia serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT gherghiceanumihaela serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT ceafalanlauracristina serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease
AT popescubogdanovidiu serumandfecalmarkersofintestinalinflammationandintestinalbarrierpermeabilityareelevatedinparkinsonsdisease